Text Size

Biodegradable intraocular therapies for retinal disorders: Progress to date

Kuno N., Fujii S.


  • 2010
  • Drugs and Aging
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Drug Delivery

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16, Takayama-cho, Ikoma-shi, Nara 630-0101, Japan

Related Publications

STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators


Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022